Anzeige
Mehr »
Montag, 27.10.2025 - Börsentäglich über 12.000 News
Automatisierung ist das neue Gold: Telescope Innovations erfindet Entdeckung von Medizin & Materialien neu!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von BioPharma Dive

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
10.10.Evommune files for IPO to advance immune drug work
09.10.Novo joins MASH dealmaking surge with $4.7B Akero buyout
09.10.Regeneron, needing a turnaround, gains new use for cancer drug
08.10.Arthrosi snags $153M in pursuit of a new gout drug
08.10.Venture firms pour $101M into a biotech using the brain to fix the immune system
08.10.Zenas looks to China to stock pipeline with 3 more immune drugs
08.10.Boehringer Ingelheim drug wins FDA OK in tough-to-treat lung disease
07.10.Peter Marks, former top FDA vaccine official, joins Eli Lilly
07.10.MapLight uses workaround to tee up IPO during government shutdown
07.10.Lexeo says FDA open to speedier approval of rare disease gene therapy
06.10.AstraZeneca, Daiichi drug extends survival in hard-to-treat breast cancer
06.10.Skye shares crash as obesity drug falls short in key study
06.10.Chiesi buys into Arbor gene editing drug for rare kidney disease
06.10.The advantage of engaging patient recruitment partners as strategic allies, not emergency backups
06.10.Immune reset: How T cell engagers can change the autoimmune treatment landscape
03.10.AI could transform healthcare. Can safety-net providers keep up?
03.10.FDA clears generic abortion pill; CMS punts 'combo drug' guidance
02.10.Amgen claims 'landmark' study result that could widen heart drug's use
02.10.Galapagos to decide on fate of cell therapy business 'within weeks'
02.10.Cartography secures $67M in pursuit of 'differentiated' cancer drugs
01.10.Takeda, in reversal, abandons cell therapy research
01.10.The top biopharma conferences in 2026
01.10.A new biotech aims to get RNA drugs into the brain
01.10.As shutdown begins, FDA to stop accepting new drug submissions
01.10.FDA official's comments spark Aurinia sell-off; Halozyme buys a biotech